Products Fluconazole
Fluconazole Pre-clinical Completed 💤 Quiet Meningitis, Cryptococcal, HIV Infections
About Fluconazole Fluconazole is a pre-clinical stage product being developed by Pfizer for Meningitis, Cryptococcal. The current trial status is completed. This product is registered under clinical trial identifier NCT00002077. Target conditions include Meningitis, Cryptococcal, HIV Infections.
Clinical Trials (14) NCT ID Phase Status Start Completion Indication NCT00002077 Pre-clinical Completed — — Meningitis, Cryptococcal NCT00002306 Pre-clinical Completed — — Meningitis, Cryptococcal NCT00000627 Pre-clinical Completed — Nov 1, 1994 HIV Infections NCT00002040 Pre-clinical Completed — — Meningitis, Cryptococcal NCT00002010 Pre-clinical Completed — — Meningitis NCT00002325 Pre-clinical Completed — — Mycoses NCT00000744 Pre-clinical Completed — Dec 1, 1995 Candidiasis NCT00002339 Phase 3 Completed — — Candidiasis, Esophageal NCT00002038 Pre-clinical Completed — — Candidiasis NCT00002294 Pre-clinical Completed — — Meningitis, Cryptococcal NCT00002076 Pre-clinical Completed — — Meningitis, Cryptococcal NCT01806623 Phase 3 Completed Mar 5, 2013 Nov 22, 2013 Vulvovaginal Candidiasis NCT01680458 Pre-clinical Completed Nov 1, 2012 Oct 1, 2014 Deep Mycosis NCT00645242 Phase 3 Completed Nov 1, 2002 Mar 1, 2003 Tinea Capitis
Product Company Stage Hype Score RotaTeq® + NeisVac-C® Merck Phase 3 Daptomycin Merck Pre-clinical Meningococcal ACWY conjugate vaccine Novartis Phase 3 Placebo + Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine + Quadrivalent Human Papillomavirus Vaccine + MenACWY-CRM Conjugate Vaccine + Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine + Quadrivalent Human Papillomavirus Vaccine Novartis Approved Meningococcal ACWY Conjugate Vaccine + DTaP-IPV-HBV + Hib + Rotavirus + Pneumococcal 7-valent Conjugate Vaccine + HAV + MMR-V + DTaP Novartis Phase 3 Meningococcal (Groups A, C, Y and W-135) Conjugate + Meningococcal polysaccharide A, C, Y and W135 and Menveo Novartis Phase 3 Meningococcal ACWY conjugate vaccine Novartis Phase 3 MenACWY-CRM + MenC-CRM + DTaP-Hib-IPV + PC7 + MMR + Varicella Novartis Phase 2 Hib-CRM197 + Hib-TT Novartis Phase 3 Novartis Meningococcal ACWY Conjugate Vaccine + Tdap Vaccine + Novartis Meningococcal ACWY Conjugate Vaccine Novartis Phase 3 MenACWY-CRM conjugate vaccine, adjuvanted + MenACWY polysaccharide vaccine + MenACWY-CRM conjugate vaccine, unadjuvanted Novartis Phase 2 meningococcal B vaccine & meningococcal ACYW conjugate vaccine Novartis Phase 2 Efungumab (Mycograb) + placebo + Amphotericin B + 5 flucytosine Novartis Phase 2 4CMenB Novartis Approved Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine Novartis Phase 3 Meningococcal (group B) multicomponent recombinant adsorbed vaccine Novartis Phase 3 MenACWY-CRM197 (two doses) + MenC + PCV7 + DTPa-IPV-HepB-Hib + MenACWY-CRM197 (one dose) Novartis Phase 3 MenACWY-CRM197 + DTaP (Diptheria, Tetanus, Pertussis) Vaccine + Hib (Haemophilus influenza b) Vaccine + IPV (Inactivated Polio Vaccine) Vaccine + Pneumococcal conjugate Vaccine + MMR (Measles, Mumps, and Rubella) Vaccine + Varicella Vaccine + Hepatitis A Virus Novartis Phase 3 Meningococcal ACWY Polysaccharide Vaccine + MenACWY CRM (19 to 55 years) + Meningococcal ACWY Conjugate Vaccine + Novartis MenACWY Vaccine (56 to 65 Years) Novartis Phase 3 Meningococcal B vaccine + Meningococcal B vaccine + Meningococcal B vaccine + Meningococcal B vaccine + Meningococcal B vaccine + Meningococcal B vaccine + Control + Meningococcal B vaccine with antipyretic Novartis Phase 2
Other Products from Pfizer